loading
Schlusskurs vom Vortag:
$2.04
Offen:
$1.99
24-Stunden-Volumen:
2,816
Relative Volume:
0.24
Marktkapitalisierung:
$11.46M
Einnahmen:
$2.35M
Nettoeinkommen (Verlust:
$-2.56M
KGV:
-4.4856
EPS:
-0.4481
Netto-Cashflow:
-
1W Leistung:
-6.94%
1M Leistung:
-1.93%
6M Leistung:
-15.19%
1J Leistung:
+14.20%
1-Tages-Spanne:
Value
$1.99
$2.14
1-Wochen-Bereich:
Value
$1.96
$2.15
52-Wochen-Spanne:
Value
$1.65
$5.96

Immuron Limited Adr Stock (IMRN) Company Profile

Name
Firmenname
Immuron Limited Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
7
Name
Twitter
@ImmuronLtd
Name
Nächster Verdiensttermin
2024-08-27
Name
Neueste SEC-Einreichungen
Name
IMRN's Discussions on Twitter

Vergleichen Sie IMRN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IMRN
Immuron Limited Adr
2.01 11.46M 2.35M -2.56M 0 -0.4481
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
481.16 123.91B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
722.07 78.94B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
657.97 39.98B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
278.25 35.89B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
119.94 28.75B 3.30B -501.07M 1.03B -2.1146

Immuron Limited Adr Aktie (IMRN) Neueste Nachrichten

pulisher
Jan 30, 2025

Immuron: Targeted oral antibodies to treat infectious diseases - Innovation News Network

Jan 30, 2025
pulisher
Jan 17, 2025

Immuron Travelan® continued strong sales growth - GlobeNewswire Inc.

Jan 17, 2025
pulisher
Nov 18, 2024

Immuron to Present at Q4 Virtual Investor Summit: Gut Disease Pipeline Showcase | IMRN Stock News - StockTitan

Nov 18, 2024
pulisher
Oct 15, 2024

Immuron Travelan® continued strong sales growth - Quantisnow

Oct 15, 2024
pulisher
Oct 04, 2024

NMRC Reports Results for Campylobacter Controlled Human Infection Model Study - The Manila Times

Oct 04, 2024
pulisher
Sep 12, 2024

IMRNImmuron Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan

Sep 12, 2024
pulisher
Sep 06, 2024

Immuron: US FDA provides favourable feedback ahead of investigational new drug application for IMM-529 - Proactive Investors Australia

Sep 06, 2024
pulisher
Sep 05, 2024

Immuron Plans Phase 2 Trial for IMM-529 following FDA review - Markets Insider

Sep 05, 2024
pulisher
Sep 05, 2024

Immuron Plans Phase 2 Trial for IMM-529 following FDA review | Daily Guardian - Daily Guardian Canada

Sep 05, 2024
pulisher
Aug 16, 2024

Immuron secures new US DoD research award - Investing.com

Aug 16, 2024
pulisher
Aug 16, 2024

Immuron secures new US DoD research award By Investing.com - Investing.com Australia

Aug 16, 2024
pulisher
Apr 10, 2024

Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Markets Insider

Apr 10, 2024
pulisher
Mar 08, 2024

U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com India

Mar 08, 2024
pulisher
May 16, 2023

Immuron Limited Announces Participation in the LD Micro Invitational XIII - The Kingston Whig-Standard

May 16, 2023
pulisher
Jan 25, 2023

Immuron US DoD Naval Medical Research Center responds to - GlobeNewswire

Jan 25, 2023
pulisher
Dec 01, 2022

Immuron Surges On U.S. DoD Funding For Travelan Research By Investing.com - Investing.com Nigeria

Dec 01, 2022
pulisher
Jul 26, 2022

Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic - StockTitan

Jul 26, 2022
pulisher
Feb 03, 2020

Immuron’s Technology Platform of Treatments in the Age of the Coronavirus Outbreak - GlobeNewswire

Feb 03, 2020
pulisher
Jun 27, 2018

Immuron Limited Trade Ideas — NASDAQ:IMRN - TradingView

Jun 27, 2018
pulisher
Mar 08, 2018

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.33% - Investing.com

Mar 08, 2018
pulisher
Mar 07, 2018

Immuron Limited Issues Correction to Misleading Halt Announcement Headline - GlobeNewswire

Mar 07, 2018
pulisher
Jan 31, 2016

Pharma & Biotech - Proactive Investors USA

Jan 31, 2016

Finanzdaten der Immuron Limited Adr-Aktie (IMRN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$80.78
price down icon 0.82%
$20.67
price down icon 0.53%
$353.75
price down icon 0.12%
$5.04
price down icon 2.14%
biotechnology ONC
$228.87
price up icon 0.53%
$119.94
price down icon 1.99%
Kapitalisierung:     |  Volumen (24h):